schizophrenic patient is placed, ranging from €67.4 per day in a day centre, to €164 per day in a long term residency or €315.7 per day in a mental health unit of a general hospital, where most stays are currently taking place in Spain. CONCLUSIONS: Following the deinstitutionalisation process of psychiatric patients that has occurred in most Western countries, in Spain, we observe an increase in admissions rates linked to a decrease in LOS for schizophrenic patients. The changing patterns of use of hospital resources parallel to the changes in community care, mean that the costs have varied complementarily throughout this reform process. These trends could have important implications for policy makers and health care providers.
Schmeding A 1 , Bridges JF 2 , Rudolph I 1 1 Janssen-Cilag GmbH, Neuss, Germany, 2 Johns Hopkins University, Bloomberg School of Public Health, Baltimore, MD, USA Poor compliance of schizophrenic patients is well known and linked to negative treatment outcomes. To address persistent issues of compliance we need to adopt a more patient centric approach towards evaluation of medicine with an aim to better appreciate the requirements of patients. OBJECTIVES: To identify patient requirements towards drug characteristics, with further emphasis on route of administration, and to examine if attitudes are modified with experience with a depot. METHODS: Based on 13 relevant drug characteristics, extracted through patient focus groups [n = 20] and literature a survey instrument was developed. Respondents were asked to rank and then rate the factors using 5-point Likert scales. Respondents included depot naïve [n = 33], depot experienced [n = 34], and patients currently on depot [n = 38]). Data was analyzed using descriptive statistics. RESULTS: In aggregate, patients ranked avoidance of dyskinesia (79.25), positive influence on sleep (75.25), onset of action (72.75), and no/little weight gain (72.25) as important drug characteristics. The least rated factors were no/little interaction with alcohol (52.75) and drug costs (53.5). With regard to differences between patients experiences with a depot, current depot users gave frequency of application a higher ranking (Rank 4 vs. Ranks 8,8). The preference for a depot formulation was highly dependent on previous experience (depot: 84%, depot experience: 29%, depot-naïve: 3%, p < 0.05), with an overall preferred frequency of injection every four weeks. CONCLUSIONS: Patients with Schizophrenia are capable and willing to share their attitudes about key processes related to the medical management of schizophrenia. Incorporating patient preferences into decision making offers an opportunity to better understand issues of adherence and management of therapy. Experience with a depot medication seems to lead to higher acceptance and appreciation of such formulations. More research is need to understand if these differences are related a optimal selection of medication or a learning by doing phenomena.
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SWITCHING OF ANTIPSYCHOTICS FROM THE PATIENTS POINT OF VIEW: RESULTS OF A QUANTITATIVE PATIENT SURVEY
Schmeding A 1 , Bormann L 2 , Klose N 1 , Ibach B 1 1 Janssen-Cilag GmbH, Neuss, Germany, 2 GfK AG, Nürnberg, Germany OBJECTIVES: Considering the patients point of view in treatment decision making is crucial for a successful therapy. In con-trast to somatic diseases in schizophrenia there are only few examples where the patients attitude and point of view was systematically recorded. Objective of the study was to collect the attitude of schizophrenic patients towards generic substitution of atypical antipsychotics. METHODS: In the quantitative survey schizophrenic patients, capable to give one's consent, aged 18-60 years were interviewed on the basis of a structured questionnaire. All participants received a second generation antipsychotic for at least one year. Getting in contact with the patients was facilitated via practice-based psychiatrists who secured the recruitment of the appropriate patients in line with the screening criteria. RESULTS: The survey was conducted in November/December 2007. 104 patients (AE 41.2 Ϯ 11.1 yrs.; AE treatment duration 3.5 Ϯ 3.2 yrs.). According to the patients' information drug treatment was changed 1.7 times on average during the last 5 years (range 1-14). In case of a generic substitution initiated by the attending physician 69% of the patients expressed a willingness to take the medication further on. The acceptance of a treatment switch was reduced if the switch was not justified by a lack of efficacy/tolerability (28%). Especially the regular switch of drugs with the same agent in the pharmacy would be met with a refusal as voiced by 76% of the patients. CONCLUSIONS: The study shows that the conduction of a quantitative survey with schizophrenic patients is feasible and differentiated statements regarding patients' attitudes towards pharmacotherapy can be generated. The results emphasize the importance of an extensive education of the patients prior to a generic substitution in order to support therapy adherence, which is fragile per se. Physicians are expected to fulfill this educational task.
PMH38 CAN PATIENTS WITH SCHIZOPHRENIA COMPLETE A CONJOINT ANALYSIS? EVIDENCE FROM GERMANY
Bridges JF, Kinter ET Johns Hopkins University, Bloomberg School of Public Health, Baltimore, MD, USA Patient preferences are an important indicator of patients' underlying values and could enlighten literatures on both compliance and satisfaction with treatment. Patient preference methods, such as conjoint analysis, are increasingly used in clinical areas, but applications in mental health remain limited. OBJECTIVES: To determine the capability of patients with schizophrenia to complete a conjoint analysis questionnaire, document patients' reactions to conjoint tasks and assess the validity and reliability of their responses. METHODS: Attributes and levels relating to the medical management of schizophrenia were identified through patient focus groups and literature reviews to create simple conjoint analysis task of six attributes with two levels each. Respondents (n = 25) were patients diagnosed with at least one episode of schizophrenia, presently stable and undergoing therapy with a neuroleptic medication and were recruited through clinics from four cities in Germany. The majority of respondents were presented with eight paired-comparisons; but a limited number of respondents were presented with sets of four scenarios to test satiation. Questionnaires were administered in person with limited explanation, were audio recorded and later analyzed. RESULTS: Respondents easily completed the conjoint tasks and results were consistent with underlying hypotheses. Specifically we identified four statistically significant factors: i) ability to think clearly (p > 0.001); ii) tiredness (p > 0.001); iii) having a supportive physician (p > 0.001); and iv) the ability to participate in social activities (p > 0.005). The reliability of responses based test-retest was high, 82.35% agreement between responses, Kappa 0.648 (p > 0.0001). Patients could also complete more complicated tasks based on choice among four Abstracts A591
